1. Median overall survival and progression-free survival were greater in the tebentafusp group compared to the control group. 2. Adverse events were generally similar between both groups, with rash the most common presentation. Evidence Rating Level: 1 (Excellent) Study Rundown: Almost 50% of patients who have uveal melanoma are affected by metastatic disease, which is associated